DOCSLIB.ORG

3D-QSAR Study of Hallucinogenic Phenylalkylamines by Using Comfa Approach

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3D-QSAR Study of Hallucinogenic Phenylalkylamines by Using Comfa Approach J Comput Aided Mol Des (2007) 21:145–153 DOI 10.1007/s10822-006-9090-y ORIGINAL PAPER 3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approach Zhuoyong Zhang Æ Liying An Æ Wenxiang Hu Æ Yuhong Xiang Received: 4 July 2006 / Accepted: 22 October 2006 / Published online: 4 January 2007 Ó Springer Science+Business Media B.V. 2006 Abstract The three-dimensional quantitative struc- Keywords 3D-QSAR Á Amphetamines Á CoMFA Á ture–activity relationship (3D-QSAR) has been stud- Hallucinogen Á Phenylethylamines ied on 90 hallucinogenic phenylalkylamines by the comparative molecular field analysis (CoMFA). Two conformations were compared during the modeling. Introduction Conformation I referred to the amino group close to ring position 6 and conformation II related to the Hallucinogens are substances that provoke strong amino group trans to the phenyl ring. Satisfactory mental and psychic changes including disorientation, results were obtained by using both conformations. derealization and depersonalization, giving rise to a There were still differences between the two models. variety of abnormal phenomena [1]. In some countries, The model based on conformation I got better statis- they are used as components of drugs. Some people tical results than the one about conformation II. And especially young people show a special interest and this may suggest that conformation I be preponderant may be addicted to these drugs for stimulation and self- when the hallucinogenic phenylalkylamines interact realization effects. And more seriously, hallucinogens with the receptor. To further confirm the predictive may be used to produce terror events by terrorists. To capability of the CoMFA model, 18 compounds with ensure the safety and the peace, strict administration conformation I were randomly selected as a test set and fast monitoring of hallucinogens are required. and the remaining ones as training set. The best Hallucinogens include mainly two categories of CoMFA model based on the training set had a cross- compounds according to their chemical structure. validation coefficient q2 of 0.549 at five components One is phenylalkylamines (phenylethylamines and and non cross-validation coefficient R2 of 0.835, the amphetamines), and the other is indolealkylamines standard error of estimation was 0.219. The model such as tryptamines and lysergic acid diethylamide showed good predictive ability in the external test with (LSD) derivatives .The 5-HT2A receptor is consid- 2 a coefficient Rpre of 0.611. The CoMFA coefficient ered to act as the biological target of these com- contour maps suggested that both steric and electro- pounds [2], however, the three-dimensional structure static interactions play an important role. The contri- of 5-HT2A receptor is not available so far, so most butions from the steric and electrostatic fields were studies are based on homologous compounds. To 0.450 and 0.550, respectively. understand the activity of hallucinogens at molecular level, their quantitative structure–activity relation- ships (QSARs) have been studied and several QSAR models have been established [3–7]. Most of the models were based on quantum chemistry parameters & Z. Zhang ( ) Á L. An Á W. Hu Á Y. Xiang or physical chemistry parameters, and the computa- Department of Chemistry, Capital Normal University, 105 Xisanhuan North, Beijing 100037, P.R. China tion based on quantum chemistry is slow and time- e-mail: [email protected] consuming. 123 146 J Comput Aided Mol Des (2007) 21:145–153 Comparative Molecular Field Analysis (CoMFA) USA) on a personal computer with Pentium IV pro- was developed by Cramer [8], and this method has cessor. Molecular building was done with molecular been well established for ligand-based 3D-QSAR sketch program. Since the crystal structure of DOET studies [9, 10]. It is based upon the calculated energies (4-ethyl-2,5-dimethoxyamphetamine) has been re- of steric and electrostatic interactions between the ported [11], the rest of the molecules were constructed compound and the probe atom placed at the various using DOET as template. Active conformation selec- intersections of a regular 3-D lattice. After this region tion is a key step for CoMFA analysis. Conformation is generated, the results are compared to the pharma- with the lowest energy is not always the active confor- cological data, and a linear combination of these two mation, and the proper active conformation can only be sets of data is constructed using a partial least squares extracted from the crystal structure of the complex of (PLS) algorithm. Cross-validated and non-cross- the drug molecule and its binding receptor [12–13]. validated r2-values are determined based on the PLS There are mainly two lower conformations for these results in order to validate the predictive properties of compounds (Fig. 1), conformation I referred to the the model. The r2-values can be optimized by itera- amino group close to ring position 6 and conformation tively varying the alignment rules, conformations and II related to the amino group trans to the phenyl ring. other parameters inherent to the technique. Energy comparison showed that conformation I was In this paper, the 3D-QSAR models of 90 phen- more stable than conformation II. To better understand ylalkylamines were established by CoMFA method. the activities of these compounds, the both conforma- This general procedure has been used in the present tions were used to build the models. The crystal con- study to gain insight into the steric and the electrostatic formation of DOET is similar to conformation I. The properties of these hallucinogenic phenylalkylamines, second conformation was acquired by interchange the their influence on the activity and to derive predictive positions of amino group and the methyl group 3D-QSAR models for discovery and prediction of the (amphetamines) or hydrogen atom (phenylethylam- hallucinogenic activities of new analogs for this class of ines). Partial atomic charges were assigned to each hallucinogens. atom and then energy minimization of each molecule was performed using Powell method and Tripos stan- dard force field with a distance-dependent dielectric Data set and methodology function. The minimization was terminated when the energy gradient convergence criterion of 0.005 kcal/ Biological data mol was reached or when the 2000-step minimization cycle limit was exceeded. The structures of 90 phenylalkylamine compounds and Molecular alignment is considered as one of the the biological activities data were cited from the ref- most sensitive parameters in CoMFA analysis [14]. erence [5]. This biological data were collected by The quality and the predictive ability of the model are Shulgin and co-workers. The reported work was about directly dependent on the alignment rule. Once the the hallucinogenic effect on human (oral activity data) active conformation was determined, pharmacophore and it has been considered as a benchmark in QSAR or common substructure alignment was carried out studies. The activities (in Mescaline units) were the according to some rules. In this paper, common sub- ratio of the effective dose of mescaline (350 mg) to the structure alignment was carried out using database mean of the threshold dose of the trial drug and the alignment tool with compound DOB as the template dose required to obtain the full effect. In the following molecule (Fig. 2). To refine the superimposition, some discussion, the alphabet A stands for the relative bio- molecules were manually adjusted using the rotation logical activity, Logarithm of A (log A) was applied in tools. Alignment of all compounds was shown in Fig. 3. the process of modeling. The structures and activity data of all the compounds were sorted by their struc- CoMFA analysis ture character and were listed in Tables 1a, b and c, respectively. Eighteen compounds were randomly In 3D-QSAR analysis, all aligned molecules were put selected as test set marked with asterisks in the tables. into a 3D cubic lattice that extending at least 0.4 nm beyond the volumes of all investigated molecules on all Molecular structure building and alignment axes. The region was partitioned into hundreds of grids with certain grid spacing. In the CoMFA analysis, All computational studies were performed by the Lennard-Jones 6–12 and Coulomb potentials were molecular modeling package sybyl 7.1 (Tripos Inc., employed to calculate the CoMFA steric and 123 J Comput Aided Mol Des (2007) 21:145–153 147 Table 1 Structure and hallucinogenic activity of (a) Phenylethylamines, (b) amphetamines and (c) some specially substituted compounds No Designation R A Log A (a) Phenylethylamines [5] 1 Mescaline 3,4,5-trimethoxy 1 0.00 2ME* 3-ethoxy-4, 5-dimethoxy 1 0.00 3 E 3,5-dimethoxy-4-ethoxy 6 0.78 4 P 3,5-dimethoxy-4-propoxy 7 0.85 5 ASB 3,4-diethoxy-5-methoxy 1.3 0.11 6 2C-E 2,5-dimethoxy-4-ethyl 18 1.26 7 2C-D 2,5-dimethoxy-4-methyl 8 0.90 8 3-TM 3,4-dimethoxy-5-methylthio 4 0.60 9 TM 3,5-dimethoxy-4-methylthio 10 1.00 10 3-TME 3,4-dimethoxy-5-ethylthio 4 0.60 11 4-TME 3-ethoxy-4-methylthio-5-methoxy 4 0.60 12 3-TE* 3-methoxy-4-ethoxy-5-methylthio 4 0.60 13 4-TE 3,5-dimethoxy-4-ethylthio 12 1.08 14 3-TASB 3-ethylthio-4-ethoxy-5-methoxy 2 0.30 15 4-TASB 3-ethoxy-4-ethylthio-5-methoxy 4 0.60 16 5-TASB* 3,4-diethoxy-5-methylthio 2 0.30 17 TP 3,5-dimethoxy-4-propylthio 16 1.20 18 TB 3,5-dimethoxy-4-butylthio 3 0.48 19 2C-G 2,5-dimethoxy-3,4-dimethyl 11 1.04 20 2C-T-F* 2,5-dimethoxy-4-(2-fluoroethylthio) 29 1.46 21 2C-T-13 2,5-dimethoxy-4-(2-methoxyethylthio) 9
Load more

Recommended publications
  • Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
    PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
    [Show full text]
  • The Renaissance in Psychedelic Research: What Do Preclinical Models Have 2 to Offer
    CHAPTER The renaissance in psychedelic research: What do preclinical models have 2 to offer Kevin S. Murnane1 Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, United States 1Corresponding author: Tel.: +1-678-547-6290; Fax: +1-678-547-6423, e-mail address: [email protected] Abstract Human research with psychedelics is making groundbreaking discoveries. Psychedelics mod- ify enduring elements of personality and seemingly reduce anxiety, depression, and substance dependence in small but well-designed clinical studies. Psychedelics are advancing through pharmaceutical regulatory systems, and neuroimaging studies have related their extraordinary effects to select brain networks. This field is making significant basic science and translational discoveries, yet preclinical studies have lagged this renaissance in human psychedelic research. Preclinical studies have a lot to offer psychedelic research as they afford tight control of experimental parameters, subjects with documented drug histories, and the capacity to elucidate relevant signaling cascades as well as conduct invasive mechanistic studies of neurochemistry and neural circuits. Safety pharmacology, novel biomarkers, and pharmaco- kinetics can be assessed in disease state models to advance psychedelics toward clinical practice. This chapter documents the current status of psychedelic research, with the thematic argument that new preclinical studies would benefit this field. Keywords Psychedelic, Preclinical, Serotonin, Neuroimaging, Alcoholism, Anxiety, Depression, Substance dependence 1 INTRODUCTION The term psychedelic has come to be associated with a broad class of drugs with diverse chemical, pharmacological, and psychoactive effects. Alternative nomencla- tures have used hallucinogen, entheogen, psychotomimetic and other appellations to Progress in Brain Research, Volume 242, ISSN 0079-6123, https://doi.org/10.1016/bs.pbr.2018.08.003 25 © 2018 Elsevier B.V.
    [Show full text]
  • Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives Strucrure-Acfivity RELA TIONSHIPS Ma
    Biochemieal PhannaeoloR)'. Vol. 54. pp. 1361-1369, 1997. ISSN 0006-2952/97/$17.00 + 0.00 © 1997 Elsevier Scienee Ine. Al! rights reserved. PIl SOOO6-2952(97)00405·X ELSEVIER Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives STRUcruRE-ACfIVITY RELA TIONSHIPS Ma. Cecilia Scorza,* Cecilia Carrau,* Rodolfo Silveira,* GemId Zapata,Torres,t Bruce K. Casselst and Miguel Reyes,Parada*t *DIVISIÓNBIOLOGíACELULAR,INSTITUTODEINVESTIGACIONESBIOLÓGICASCLEMENTeEsTABlE, CP 11600, MONTEVIOEO,URUGUAY;ANDtDEPARTAMENTODEQUíMICA, FACULTADDECIENCIAS,UNIVERSIDADDECHILE, SANTIAGO,CHILE ABSTRACT. The monoamine oxidase (MAO) inhibitory propenies of a series of amphetamine derivatives with difTerent substituents at or around rhe para position of the aromaric ring were evaluateJ. i¡, in viero stuJies in which a crude rar brain mirochllndrial suspension was used as rhe source of MAO, several compounds showed a srrong (ICS0 in rhe submicromolar range), selecrive, reversible, time-independenr, and concenrrarion-related inhibition of MAO-A. After i.p. injection, the compounds induced an inerease of serotonin and a decrease of j-hydroxyindoleacetic acid in the raphe nuclei and hippocampus, confinning rhe in virro results. The analysis of structure-activity relationships indicates rhat: molecules with amphetamine-Iike structure and different substitutions nn the aromaric ring are potentially MAO-A inhibitors; substituents at different positions of the aromatic ring moditY the porency but have litde inf1uence "n the selectiviry; substituents at rhe para position sllch as ,lmino, alkoxyl. halogens. or alkylthio produce a significant increase in rhe acrivity; the para-substituent musr be an e1ectron Jonor; hulky ~roups next to rhe para subsriruent Icad ro a Jecrease in the actÍ\'ityi ,ubstiruents loearcd ar posirions more Jistant ,m rhe aromaric ring havc less intluence anJ, even when the subsriruent is '1 halogen (CI, Br), an increase in rhe acrivity "f rhe cllmpound is llbtained.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE
    Novel Psychoactive Treatment UK Network NEPTUNE Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE This publication of the Novel Psychoactive Treatment UK Network (NEPTUNE) is protected by copyright. The reproduction of NEPTUNE guidance is authorised, provided the source is acknowledged. © 2015 NEPTUNE (Novel Psychoactive Treatment UK Network) 2015 Club Drug Clinic/CAPS Central and North West London NHS Foundation Trust (CNWL) 69 Warwick Road Earls Court SW5 9HB http://www.Neptune-clinical-guidance.com http://www.Neptune-clinical-guidance.co.uk The guidance is based on a combination of literature review and expert clinical con sensus and is based on information available up to March 2015. We accept no responsi bility or liability for any consequences arising from the use of the information contained in this document. The recommended citation of this document is: Abdulrahim D & Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. Novel Psychoactive Treatment UK Network (NEPTUNE). London, 2015. NEPTUNE is funded by the Health Foundation, an independent charity working to improve the quality of health care in the UK. Editorial production and page design by Ralph Footring Ltd, http://www.footring.co.uk NEPTUNE NEPTUNE (Novel Psychoactive Treatment UK Network): Expert Group members NEPTUNE Expert Group Dr Owen Bowden-Jones Neptune Chair Clinical and programme lead Consultant
    [Show full text]
  • Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines
    ORIGINAL RESEARCH published: 28 November 2019 doi: 10.3389/fphar.2019.01423 Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines Karolina E. Kolaczynska 1, Dino Luethi 1,2, Daniel Trachsel 3, Marius C. Hoener 4 and Matthias E. Liechti 1* 1 Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland, 2 Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Vienna, Austria, 3 ReseaChem GmbH, Burgdorf, Switzerland, 4 Neuroscience Research, pRED, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland Background: 2,4,5-Trimethoxyamphetamine (TMA-2) is a potent psychedelic compound. Structurally related 4-alkyloxy-substituted 2,5-dimethoxyamphetamines and phenethylamine congeners (2C-O derivatives) have been described but their pharmacology Edited by: is mostly undefined. Therefore, we examined receptor binding and activation profiles of M. Foster Olive, these derivatives at monoamine receptors and transporters. Arizona State University, United States Methods: Receptor binding affinities were determined at the serotonergic 5-HT1A, 5-HT2A, Reviewed by: Luc Maroteaux, and 5-HT2C receptors, trace amine-associated receptor 1 (TAAR1), adrenergic α1 and INSERM U839 Institut du Fer à α2 receptors, dopaminergic D2 receptor, and at monoamine transporters, using target- Moulin, France Simon D. Brandt, transfected cells. Additionally, activation of 5-HT2A and 5-HT2B receptors and TAAR1 was Liverpool John Moores University, determined. Furthermore, we assessed monoamine transporter inhibition. United Kingdom Results: Both the phenethylamine and amphetamine derivatives (Ki = 8–1700 nM and *Correspondence: Matthias E. Liechti 61–4400 nM, respectively) bound with moderate to high affinities to the 5-HT2A receptor [email protected] with preference over the 5-HT1A and 5-HT2C receptors (5-HT2A/5-HT1A = 1.4–333 and Specialty section: 5-HT2A/5-HT2C = 2.1–14, respectively).
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Health and Safety Code Chapter 481. Texas Controlled Substances
    HEALTH AND SAFETY CODE TITLE 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES SUBTITLE C. SUBSTANCE ABUSE REGULATION AND CRIMES CHAPTER 481. TEXAS CONTROLLED SUBSTANCES ACT SUBCHAPTER A. GENERAL PROVISIONS Sec.A481.001.AASHORT TITLE. This chapter may be cited as the Texas Controlled Substances Act. Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989. Sec.A481.002.AADEFINITIONS. In this chapter: (1)AA"Administer" means to directly apply a controlled substance by injection, inhalation, ingestion, or other means to the body of a patient or research subject by: (A)AAa practitioner or an agent of the practitioner in the presence of the practitioner; or (B)AAthe patient or research subject at the direction and in the presence of a practitioner. (2)AA"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. The term does not include a common or contract carrier, public warehouseman, or employee of a carrier or warehouseman acting in the usual and lawful course of employment. (3)AA"Commissioner" means the commissioner of state health services or the commissioner 's designee. (4)AA"Controlled premises" means: (A)AAa place where original or other records or documents required under this chapter are kept or are required to be kept; or (B)AAa place, including a factory, warehouse, other establishment, or conveyance, where a person registered under this chapter may lawfully hold, manufacture, distribute, dispense, administer, possess, or otherwise dispose of a controlled substance or other item governed by the federal Controlled Substances Act (21 U.S.C.
    [Show full text]
  • Self Unbound: Ego Dissolution in Psychedelic Experience Chris Letheby*,‡ and Philip Gerrans‡
    Neuroscience of Consciousness, 2017, 1–11 doi: 10.1093/nc/nix016 Opinion Paper Self unbound: ego dissolution in psychedelic experience Chris Letheby*,‡ and Philip Gerrans‡ Department of Philosophy, University of Adelaide, North Terrace, Adelaide, South Australia 5005, Australia *Correspondence address. Department of Philosophy, University of Adelaide, North Terrace, Adelaide SA 5005, Australia. Tel: +61 08 8313 4249, Fax: +61 08 8313 4341. E-mail: [email protected] ‡Both authors contributed equally to the development of the arguments and the writing of the manuscript. C.L. proofread, formatted, and prepared the manuscript for submission. Abstract Users of psychedelic drugs often report that their sense of being a self or ‘I’ distinct from the rest of the world has dimin- ished or altogether dissolved. Neuroscientific study of such ‘ego dissolution’ experiences offers a window onto the nature of self-awareness. We argue that ego dissolution is best explained by an account that explains self-awareness as resulting from the integrated functioning of hierarchical predictive models which posit the existence of a stable and unchanging en- tity to which representations are bound. Combining recent work on the ‘integrative self’ and the phenomenon of self- binding with predictive processing principles yields an explanation of ego dissolution according to which self- representation is a useful Cartesian fiction: an ultimately false representation of a simple and enduring substance to which attributes are bound which serves to integrate and unify cognitive processing across levels and domains. The self-model is not a mere narrative posit, as some have suggested; it has a more robust and ubiquitous cognitive function than that.
    [Show full text]
  • Novel Hallucinogens and Plant-Derived Highs
    Novel Hallucinogens and Plant-Derived Highs Emily Dye Forensic Chemist Special Testing and Research Laboratory Drug Enforcement Administration Outline • Hallucinogens • Plant-Derived Highs – 2C Compounds – Kratom – NBOMe Compounds – Fly Agaric Mushrooms – DOX Compounds – Kava Kava – Kanna • Empathogens – Aminoindanes – APDB – APB DEA Special Testing and Research Laboratory Emerging Trends Program 2C Compounds • Psychedelic phenethylamines • Synthesized by Alexander Shulgin – Published in PiHKAL • 27 known compounds – Most common: 2C-C, 2C-B, and 2C-I DEA Special Testing and Research Laboratory Emerging Trends Program 2C Compounds DEA Special Testing and Research Laboratory Emerging Trends Program 2C-B-FLY • Psychedelic phenethylamine • Synthesized by Aaron Monte www.erowid.org DEA Special Testing and Research Laboratory Emerging Trends Program Bromo-DragonFLY • Psychedelic phenethylamine • Synthesized in the lab of David Nichols • Deaths associated with misrepresentation as 2C-B-FLY www.erowid.org DEA Special Testing and Research Laboratory Emerging Trends Program NBOMe Compounds • Hallucinogenic phenethylamines • Synthesized by Heim, et al. • Isomers can be distinguished via RT and MS DEA Special Testing and Research Laboratory Emerging Trends Program Name R1 R2 R3 R4 Name R1 R2 R3 R4 25B-NB2OMe Br OCH3 H H 25N-NB2OMe NO2 OCH3 H H 25B-NB3OMe Br H OCH3 H 25N-NB3OMe NO2 H OCH3 H 25B-NB4OMe Br H H OCH3 25N-NB4OMe NO2 H H OCH3 25C-NB2OMe Cl OCH3 H H 25P-NB2OMe CH2CH2CH3 OCH3 H H 25C-NB3OMe Cl H OCH3 H 25P-NB3OMe CH2CH2CH3 H OCH3 H 25C-NB4OMe
    [Show full text]
  • Exploring the Relationship Between Microdosing, Personality and Emotional Insight: a Prospective Study
    Exploring the relationship between microdosing, personality and emotional insight: A prospective study Journal of Psychedelic HANNAH M. DRESSLER1 , STEPHEN J. BRIGHT2 and Studies VINCE POLITO3p 5 (2021) 1, 9–16 1 Georg Elias Mueller Institute of Psychology, University of Gottingen,€ Goßlerstraße 14, 37073 DOI: Gottingen,€ Germany 10.1556/2054.2021.00157 © 2021 The Author(s) 2 School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, 6027, Australia 3 Department of Cognitive Science, Macquarie University, NSW, 2109, Australia Received: October 24, 2020 • Accepted: February 22, 2021 Published online: March 24, 2021 ORIGINAL RESEARCH PAPER ABSTRACT Backround and aims: Having entered the recent public and research zeitgeist, microdosing involves consuming sub-perceptual doses of psychedelic drugs, allegedly to enhance performance, creativity, and wellbeing. The results of research to date have been mixed. Whereas most studies have reported positive impacts of microdosing, some microdosers have also reported adverse effects. In addition, research to date has revealed inconsistent patterns of change in personality traits. This prospective study explored the relationship between microdosing, personality change, and emotional awareness. Methods: Measures of personality and alexithymia were collected at two time points. 76 microdosers participated at baseline. Invitations to a follow-up survey were sent out after 31 days, and 24 par- ticipants were retained. Results: Conscientiousness increased, while neuroticism decreased across thesetimepoints(n 5 24). At baseline (N 5 76), neuroticism was associated with alexithymia. In addition, neuroticism correlated negatively with duration of prior microdosing experience, and ex- traversion correlated positively with both duration of prior microdosing experience and lifetime number of microdoses. Conclusion: These results suggest that microdosing might have an impact on otherwise stable personality traits.
    [Show full text]